|
👨💻 Nitrosamines Conversations -Coming Soon! 🎙
|
|
0
|
145
|
June 25, 2026
|
|
Recrystallization can stop nitrosamine formation in ranitidine hydrochloride - PUB
|
|
1
|
252
|
June 24, 2026
|
|
NDBA interference on Parecoxib testing?
|
|
3
|
164
|
June 23, 2026
|
|
During analysis NDELA Area observed dropped in standard solution after running sample what could be the reason
|
|
1
|
94
|
June 23, 2026
|
|
A Robust and Universal LC–MS/MS Method for Determination of N-Nitrosodimethylamine in Pharmaceuticals Using a C30 Column -Pub
|
|
1
|
206
|
June 22, 2026
|
|
Nitrosamines & Genotoxic Impurities in Pharmaceutical Development and Manufacturing
|
|
3
|
392
|
June 21, 2026
|
|
Advancing Nitrosamine Analysis: USP Frameworks and LC-MS/MS Solutions
|
|
1
|
305
|
June 19, 2026
|
|
Why is NMEA associated with Amphotericin B? (Appendix 1 March 2026 Update)
|
|
3
|
279
|
June 19, 2026
|
|
Nitrosamine risk assessment in early clinical development
|
|
0
|
210
|
June 17, 2026
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
5611
|
June 17, 2026
|
|
Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study-Pub
|
|
1
|
157
|
June 16, 2026
|
|
Calculation of the Maximum Daily Dose (MDD) in Mouthwash Products
|
|
3
|
251
|
June 16, 2026
|
|
Rupatadine related Nitrosamine
|
|
1
|
127
|
June 15, 2026
|
|
EMA - Appendix 1 - Update
|
|
94
|
10327
|
June 15, 2026
|
|
Finasteride NDSRI
|
|
2
|
179
|
June 15, 2026
|
|
Advancing Generic Drug Development: Translating Science to Approval 2025
|
|
3
|
537
|
June 11, 2026
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
157
|
June 8, 2026
|
|
Upcoming EMA Q&A for other nitrosocompounds
|
|
3
|
471
|
June 5, 2026
|
|
The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines -Pub
|
|
0
|
92
|
June 3, 2026
|
|
👨💻 Expand the analytical toolkit for comprehensive detection of nitrosamines using SIFT-MS
|
|
0
|
128
|
June 2, 2026
|
|
An updated version of Health Canada's Guidance on nitrosamine impurities in medications(Update May 29, 2026)
|
|
0
|
322
|
June 2, 2026
|
|
MS Method Development Criterias?
|
|
1
|
177
|
June 2, 2026
|
|
For anyone attending AAPS Summer Scientific Forum
|
|
1
|
138
|
June 1, 2026
|
|
Analysis of Nitrite in Pharmaceutical Excipients: A Multi‑Laboratory Comparative Study - PUB
|
|
3
|
481
|
June 1, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
493
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
309
|
June 1, 2026
|
|
Published limit for N-Nitroso-Vonoprazan
|
|
3
|
513
|
May 29, 2026
|
|
📣 Theoretical and Experimental Assessment of Nitrosamine Risk in Industrial Solvent Recovery -Pub
|
|
3
|
575
|
May 29, 2026
|
|
Simulation of nitrosamine drug substance-related impurities from secondary amine-related impurities in approved human drug products -Pub
|
|
4
|
419
|
May 27, 2026
|
|
Why EMA still assigns AI limits (CPCA) for nitrosamines in oncology drugs
|
|
7
|
476
|
May 27, 2026
|